Nav: Home

Current Chemotherapy News and Events

Current Chemotherapy News and Events, Chemotherapy News Articles.
Sort By: Most Relevant | Most Viewed
Page 1 of 25 | 1000 Results
Reconfigurable multi-organ-on-a-chip system reliably evaluates chemotherapy toxicity
Christopher McAleer and colleagues have created a new multiorgan-on-a-chip system that can accurately capture the toxic effects of chemotherapies that have been metabolized by the liver -- effects usually not seen in standard cell culture preclinical drug development. (2019-06-19)
Terminally ill who request doctors make decisions undergo more aggressive final treatments
Terminally ill patients who request that physicians make decisions on their behalf are more likely to receive aggressive treatments in the weeks before they die, according to a Rutgers study. (2019-06-18)
IDIBELL researchers relate the amplification of a chromosomal region with resistance to to a chemotherapeutic drug in breast cancer
IDIBELL researchers relate the amplification of a chromosomal region with resistance to a chemotherapeutic drug in breast cancer. (2019-06-18)
New methods from material sciences in physics find their way into cancer research
A new study on the behavior of water in cancer cells shows how methods usually limited to physics can be of great use in cancer research. (2019-06-18)
Researchers identify traits linked to better outcomes in HPV-linked head and neck cancer
University of North Carolina Lineberger Comprehensive Cancer Center researchers identified characteristics that could be used to personalize treatment for patients with a type of head and neck cancer linked to HPV infection. (2019-06-14)
Carboplatin & paclitaxel chemotherapy alone should remain standard treatment for endometrial cancer
The New England Journal of Medicine recently published the primary endpoint of the NRG Oncology clinical trial NRG-GOG 0258, which showed that carboplatin and paclitaxel chemotherapy preceded by radiotherapy with concurrent cisplatin, or combined modality therapy, did not significantly increase recurrence-free survival for women with stage 3-4A endometrial cancer when compared to chemotherapy with carboplatin and paclitaxel alone. (2019-06-13)
A homing beacon for chemotherapy drugs
Killing tumor cells while sparing their normal counterparts is a central challenge of cancer chemotherapy. (2019-06-12)
Researchers develop drug-targeting molecules to improve cancer treatment
A compound was developed from a new material, described as an easily injected hydrogel, which acts as a 'homing' cue to attract drug molecules to sites bearing a tumor. (2019-06-12)
Determining risk of recurrence in triple-negative breast cancer
A personalized prognosis for patients diagnosed with triple-negative breast cancer was the goal of a new study by Katherine Varley, Ph.D., researcher at Huntsman Cancer Institute (HCI) and assistant professor of oncological sciences at the University of Utah. (2019-06-12)
A molecular glue to overcome cancer drug resistance?
A team led by Duke researchers has discovered a small molecule drug that can stop cancer cells from becoming resistant to chemotherapy. (2019-06-07)
Long exposure to protein inhibitor may be key to more effective chemotherapy for cancer
Researchers at SMU's Center for Drug Discovery, Design and Delivery (CD4) have succeeded in lab testing the use of chemotherapy with a specific protein inhibitor so that the chemotherapeutic is better absorbed by drug-resistant cancer cells without harming healthy cells. (2019-06-07)
Robotic surgery for throat cancer not superior to radiation therapy, study finds
In 2012, scientists at Lawson Health Research Institute launched the world's first clinical trial comparing robotic surgery to radiation therapy for the treatment of oropharyngeal cancer (cancer at the back of the throat). (2019-06-06)
Lymphoma trial finds combination targeted therapy effective prior to chemotherapy
Results of a Phase II clinical trial conducted at The University of Texas MD Anderson Cancer Center revealed that combination targeted therapy, consisting of rituximab, lenalidomide and ibrutinib (RLI), had an 84.6 percent overall response rate (ORR) and 38.5% complete response rate (CRR) when given prior to any chemotherapy for newly diagnosed patients with a specific type of diffuse large b-cell lymphoma (DLBCL). (2019-06-04)
Suggested benefit in PCV chemoradiotherapy for both IDH-mutant WHO-defined molecular subgroups
A recent, updated predictive analysis of the three WHO-defined molecular subgroups based on isocitrate dehydrogenase 1/2 (IDH) mutation status and 1p/19q co-deletion status represented in the high-risk treatment arms of the NRG Oncology clinical trial NRG-RTOG 9802 indicates that both IDH-mutant sub-groups (IDHmut-noncodel and IDHmut-codel) could benefit from the addition of PCV chemotherapy to radiotherapy treatment. (2019-06-03)
Patients who received PBI without chemotherapy experienced less fatigue, slightly poorer cosmesis
Patient-reported outcome (PRO) data indicates that partial breast irradiation (PBI) is more convenient than whole breast irradiation (WBI) for women with breast cancer who do not receive adjuvant chemotherapy. (2019-06-03)
NUS researchers uncovers promising cancer target for liposarcoma
A study conducted by a team of researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore has revealed a close association between liposarcoma (LPS), a type of cancer that develops from fat cells, and the bromodomain and extraterminal (BET) protein family. (2019-06-03)
New TAILORx data guides adjuvant therapy in younger breast cancer patients
New data from TAILORx, the largest-ever breast cancer trial, guides adjuvant therapy in younger breast cancer patients with even greater precision than the original findings: no benefit from chemotherapy if age 50 or less with a score of 16-20 on the 21-gene Recurrence Score (RS) test and at low risk, clinically (determined by tumor size/histologic grade). (2019-06-03)
Immunotherapy better than aggressive chemo as first-line treatment in head and neck cancer
Immunotherapy used with chemotherapy or on its own is a better first-line treatment for people with head and neck cancer that has returned than standard aggressive chemotherapy, new clinical trial results show. (2019-06-03)
NRG oncology trial of metformin for non-small cell lung cancer
Initial results of NRG-LU001 indicate that, although the diabetes agent metformin was well-tolerated by patients, the agent has not clearly improved progression-free survival (PFS) or overall survival (OS) for trial participants with locally advanced non-small cell lung cancer (NSCLC). (2019-06-01)
NRG trial suggests total neoadjuvant therapy for locally advanced rectal cancer is safe
Results from the first experimental arm using veliparib as part of total neoadjuvant therapy (induction chemotherapy followed by chemoradiotherapy and surgery; TNT) in patients with locally advanced rectal adenocarcinoma on the NRG Oncology Phase II clinical trial NRG-GI002 were recently presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. (2019-06-01)
ASCO: Finally, a tool to predict response to chemotherapy before bladder cancer surgery
'The idea is that for any individual tumor, its gene expression could tell us whether the cancer will respond to a certain kind of chemotherapy,' says Thomas Flaig, MD. (2019-05-31)
Female patients more likely to survive but experience worse side effects from cancer treatment
An analysis of over 3,000 patients with cancer of the esophagus and stomach suggests female patients are more likely to survive longer than male patients, but experience more nausea, vomiting and diarrhea during therapy. (2019-05-28)
Experimental fertility preservation provides hope for young men
Testicular tissue samples obtained from 189 males who were facing procedures that could imperil fertility were cryopreserved at one university, proving the feasibility of centralized processing and freezing of testicular tissue obtained from academic medical centers, including Children's National, scattered around the world. (2019-05-23)
Proton therapy for cancer lowers risk of side effects
Proton therapy results in fewer side effects than traditional X-ray radiation therapy for many cancer patients, according to a new study led by Washington University School of Medicine in St. (2019-05-22)
Using fruit flies to identify new treatment for a colorectal cancer patient
Erdem Bangi and colleagues demonstrate a new approach to developing personalized therapy for a patient with treatment-resistant colorectal cancer: using a fruit fly genetically modified with a patient's own cancer mutations to test candidate treatments. (2019-05-22)
Cancer Research UK: Less chemotherapy better for older patients with some advanced cancers
Less chemotherapy is as effective at controlling disease for elderly or frail patients with advanced cancer of the stomach or oesophagus (food pipe), and leads to fewer side effects such as diarrhoea and lethargy. (2019-05-15)
The Lancet Oncology: Global study predicts more than 50% rise in chemotherapy demand by 2040
Between 2018 and 2040, the number of patients requiring first-line chemotherapy treatment each year is predicted to rise from 9.8 million to 15 million (53%) globally, if there were full application of evidence-based guidelines. (2019-05-08)
Frequency and outcomes of new suspicious lesions on breast MRI in neoadjuvant therapy
During neoadjuvant chemotherapy, new suspicious findings detected on breast magnetic resonance imaging (MRI) during neoadjuvant therapy are most likely benign, according to a study to be presented at the ARRS 2019 Annual Meeting, set for May 5-10 in Honolulu, Hawaii. (2019-05-07)
Form drives function in cancer proliferation
A new study finds that the protein responsible for the crawling movements of cells also drives the ability of cancer cells to grow when under stress. (2019-05-06)
Stephenson Cancer Center physician is senior author on major study
A gynecologic oncologist at the Stephenson Cancer Center at OU Medicine was a national leader of a newly published research study that reveals good news for women with ovarian cancer -- longer survival times plus a treatment option that causes fewer difficult side effects. (2019-05-03)
Test allows doctors to determine most effective treatment for women with breast cancer
A breast cancer test has been found that helps doctors make treatment decisions for some breast cancer patients, following research carried out at Queen Mary University of London and funded by Cancer Research UK. (2019-04-30)
EGLN inhibitor protects normal tissue and enables RT in mouse model of pancreatic cancer
Administration of the EGLN inhibitor FG-4592 prior to ablative radiotherapy provided protection against fatal gastrointestinal bleeding and improved survival in a mouse model of unresectable pancreatic cancer. (2019-04-30)
Research decodes one way cancer survives treatment, proposes a way to prevent it
Cancer cells have various tricks up their metaphorical sleeves to survive in the face of chemotherapy, radiotherapy and other cancer treatments. (2019-04-30)
Radiotherapy after chemo may improve survival in patients with advanced Hodgkin's lymphoma
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy after chemotherapy even when all traces of the cancer appear to have gone, according to late-breaking results presented at the ESTRO 38 conference. (2019-04-28)
Genetic testing in women diagnosed with breast cancer decreases cost of care nationwide
A new study suggests that Oncotype DX-guided treatment could reduce the cost for the first year of breast cancer care in the US by about $50 million (about 2 percent of the overall costs in the first year). (2019-04-24)
Chemotherapy or not?
Case Western Reserve University researchers and partners, including a collaborator at Cleveland Clinic, are pushing the boundaries of how 'smart' diagnostic-imaging machines identify cancers -- and uncovering clues outside the tumor to tell whether a patient will respond well to chemotherapy. (2019-04-24)
Targeted therapy proves effective against aggressive rare blood cancer
Clinical study treating BPDCN with tagraxofusp led to first FDA approval for the disease. (2019-04-24)
Study of tagraxofusp reports 90% response rate for deadly blood cancer with no prior available therapies
An open-label, multi-cohort Phase II trial, led by investigators at the University of Texas MD Anderson Cancer Center, reports that treatment with the drug tagraxofusp resulted in high response rates in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare but highly aggressive -- and often fatal bone marrow and blood disorder -- for which there are no existing approved therapies. (2019-04-24)
NUS researchers identified new biomarkers associated with 'chemobrain'
Researchers from the National University of Singapore have identified new biomarkers related to the cognitive impairment associated with cancer known as chemobrain. (2019-04-23)
Air pollution poses risks for childhood cancer survivors
Study by Huntsman Cancer Institute researchers finds air pollution significantly increases the risk of hospitalizations for young cancer survivors. (2019-04-23)
Page 1 of 25 | 1000 Results
   First   Previous   Next      Last   

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Moving Forward
When the life you've built slips out of your grasp, you're often told it's best to move on. But is that true? Instead of forgetting the past, TED speakers describe how we can move forward with it. Guests include writers Nora McInerny and Suleika Jaouad, and human rights advocate Lindy Lou Isonhood.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...